After a damaging court ruling on Copaxone 40 mg and some management missteps, CEO Erez Vigodman will step down as CEO of the Israeli generic drug leader. Chairman Yitzhak Peterburg will fill in on an interim basis.
The departure of Teva Pharmaceutical Industries Ltd. CEO Erez Vigodman leaves the Israeli generic drug giant without both of the two primary architects of its $40.5bn acquisition of Allergan PLC’s generics business in 2016, potentially posing risks to the integration.
Vigodman will step down almost three years to the day after he took the helm, having failed to turn around the struggling business. Teva announced the leadership transition Feb. 7,...
In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.
Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.
AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.
